Heart Health

This news channel includes content on cardiovascular disease prevention, cardiac risk stratification, diagnosis, screening programs, and management of major risk factors that include diabetes, hypertension, diet, life style, cholesterol, obesity, ethnicity and socio-economic disparities.
 

The American Heart Association (AHA) has launched a nationwide data-driven research competition to uncover how inflammation contributes to cardiovascular risk and how it is currently addressed in clinical practice. The initiative, called the Systemic Inflammation Data Challenge, invites data scientists, clinicians, and researchers to leverage advanced analytics and electronic medical record (EMR) data to better understand the impact of systemic inflammation on atherosclerotic cardiovascular disease.

AHA data challenge explores links between inflammation and heart disease

Are care teams doing enough to take on inflammation? The American Heart Association hopes this new research initiative can help answer that question, and many others. 

Former American College of Cardiology (ACC) president Kim Allan Williams, Sr., MD, MACC, MASNC, FAHA, FESC, chair, department of medicine, University of Louisville School of Medicine, and an ACC delegate to the American Medical Association House of Delegates, discusses how cardiology should be focusing more on earlier prevention efforts in cardiology.

The power of prevention: Cardiologist says proactive patient care can make a big difference later in life

Former ACC president Kim Allan Williams Sr., MD, thinks cardiologists should be much more proactive. Encouraging healthy eating habits now, for example, can keep patients out of the hospital later in life and reduce healthcare spending.

vitamin d supplement heart health CVD

Yes, researchers argue, vitamin D supplements help protect the heart

The ongoing debate continues. The team behind this latest analysis pointed to more than 40 years of research to make its point.

aktiia hilo band cuffless blood pressure monitor

‘The start of a paradigm shift’: FDA clears first over-the-counter cuffless blood pressure monitor

The cuffless technology, which has already gained CE mark approval, should make its U.S. debut in 2026.

cardiovascular heart diagnostics

Heart attack deaths are way down after decades of breakthroughs—but other risks have skyrocketed

Researchers explored more than 52 years of data, highlighting several key trends in the Journal of the American Heart Association.

FDA finalizes new heart warnings for COVID-19 vaccines

The new warnings, first proposed to Pfizer and Moderna in April, are now officially required by the FDA. They provide additional information about the potential risks of myocarditis and/or pericarditis associated with these vaccines.

Popular obesity drugs limit amputations, heart issues among patients with peripheral artery disease

Semaglutide, tirzepatide and other GLP-1 drugs appear to provide significant value for patients with moderate PAD.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

American College of Cardiology now supports early use of medication to treat obesity

The group highlighted the proven effectiveness of these drugs, especially semaglutide and tirzepatide, while noting that eligibility, affordability and availability will still play key roles in any treatment decisions.